F_CSS_Comp Posting.pdf

COMPETITIVE

COMBINED SYNOPSIS / SOLICITATION

Title: Acquisition of Chemical Compounds for NCATS Pre-Clinical Library

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95021Q00406 and the solicitation is issued as a request for quotation (RFQ).

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures;

FAR Subpart 13.5— Simplified Procedures for Certain Commercial Items; and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2021-06, dated 07/12/2021.

(iv) The associated NAICS code 325998 and the small business size standard is 500 employees. This requirement is conducted competitively using a total small business set aside. Offers from Other than Small Businesses will not be considered.

(v) Project Requirements:

• Please see Attachment 1: List of Required Compounds

Total shipping price must be included in each offeror’s quote.

Offerors wishing to provide a quote must be able to fulfill the entire list of Required Compounds to be considered for award. Quotes that offer only partial list fulfillment will not be considered for award.

Partial Shipments will be accepted, as the Government anticipates certain compounds to be available sooner than others.

Salient Characteristics:

1. Small molecules must have validated biological and pharmacological activities.

2. Must be available for high-throughput screening (HTS) and high-content screening

(HCS).

3. Must come with detailed biological and chemical information with LC/MS and NMR reports to ensure high quality.

4. Each small molecule must be guaranteed to have a purity of >95% (accuracy +/-5%) that is to be confirmed by NMR and/or LCMS spectra.

5. In addition to the molecules themselves, the Contractor must be able to provide the following electronic information for each required molecule: chemical structure or simplified molecular-input line-entry system (SMILES) or equivalent chemical structure information, supplier ID, plate ID, well location, tube ID, concentration in millimolar, and volume in microliters. This information shall be provided via email referencing individual compound vial barcodes.

(vi) Delivery/Inspection:

Offerors shall provide on their quote a good faith delivery estimate from receipt of an order. Delivery, inspection, and acceptance will be performed at NCATS located at 9800 Medical Center Drive, Rockville, MD 20852.

(vii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Items, applies to this acquisition.

(viii) The award resulting from this solicitation will be made to the responsible offeror whose proposal is most advantageous to the Government, price and other factors considered.

The following factors shall be used to evaluate quotations: Technical Capability, Past Performance, and Price.

(ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Items, with its offer.

(x) The FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition.

The following FAR provisions or clauses are incorporated by reference:

52.211-6, Brand Name or Equal 52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-16, Commercial and Entity Code Reporting (Aug 2020) 52.204-18, Commercial and Entity Code Maintenance (Aug 2020) 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services of Equipment HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity

Investigations (December 18, 2015).

52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2020).

(xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Items, applies to this acquisition

(xii) HHS reserves the right to exercise priorities and allocations authority with respect to this contract, to include rating this order in accordance with 45 CFR Part 101, Subpart A - Health Resources Priorities and Allocations System.

(xiii) The offeror must complete and return FAR 52.204-24 with its offer.

(xiv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance;

trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations.

Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order.

In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.”

All responses must be received by September 9, 2021, 9:00 am, Eastern Standard Time and reference number 75N95021Q00406. Responses shall be submitted electronically to Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov.

Fax responses will not be accepted.

http://www.sam.gov/ mailto:kevin.alvarez@nih.gov

(xv) The name of the individual to contact for information regarding the solicitation:

Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov.

Attachments:

1. List of Required Compounds

2. FAR 52.212-5

3. Copy of FAR 52.204-24, to be completed and submitted by offeror

4. Invoice and payment provisions mailto:kevin.alvarez@nih.gov

Chemical Name StructurePack Size

Iproplatin

Dichlorodihydroxybis(isopropylamine)platinum

1100mg X

62928-11-4CAS:

Pelrinone

1,6-Dihydro-2-methyl-6-oxo-4-[(3-pyridinylmethyl)amino]-5-pyrimidinecarbonitrile; 1,4-Dihydro-2-methyl-4-oxo-6-[(3-pyridinylmethyl)amino]-5-pyrimidinecarbonitrile;

1175mg X

94386-65-9CAS:

Flestolol

ACC 9089

1150mg X

87721-62-8CAS:

alvarezkm Text Box Attachment 1: List of required compounds

Vinmegallate

(3 ,16 )-17,18-Didehydroeburnamenine-14-methanol 3,4,5- Trimethoxybenzoate; RGH 4417;

150mg X

83482-77-3CAS:

S-Amisulpride

S-(-)-Amisulpride; (S)-4-Amino-N-[(1-ethyl-2-pyrrolidinyl) methyl]-5-(ethylsulfonyl)-2-methoxybenzamide

15mg X

71675-92-8CAS:

Besulpamide 15mg X

90992-25-9CAS:

Epostane

(4 ,5 ,17 )-4,5-Epoxy-3,17-dihydroxy-4,17-dimethylandrost -2-ene-2-carbonitrile; Win 32729;

15mg X

80471-63-2CAS:

Sodium Hyaluronate

Arthrease; Artz; Artz Dispo; Artzal; Bio Hyaluro 12; Bio Sodium Hyaluronate HA 20; Chlamyhyaluronic acid sodium salt; Cystistat; Euflexxa; FCH 121-S;

FCH 150; FCH 200; FCH 248; FCH 60; FCH 80; FCH 80LE; FCH-SU;

Fermatron; HA-F; HA-Q; HA-Q 1; HA-QA; HE-QSE; Healon; Healon (polysaccharide); Healon GV; Healon V; Hyalart; Hyalein; Hyalein Mini;

Hyalgan; Hyaluronsan HA-LQ; Hyaluronsan HA-LQ1; Hyaluronsan HA-LQH;

Hyaluronsan HA-Q; Hyaluronsan HA-QSS; Hyaluronsan M 5070; Hyasol;

Hyasol BT; Hyladerm; Hylo Comod; Jointex; Khionat; NRD 101; Nidelon;

15mg X

9067-32-7CAS:

N-(4-Hydroxyphenyl)-5-methyl-2-1H-pyridone

1-(4-Hydroxyphenyl)-5-methyl-2(1H)-pyridinone; F 351; 4- Hydroxy-pirfenidone

15mg X

851518-71-3CAS:

Iomeprol

N,N'-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)methylamino] -2,4,6-triiodo -1,3-benzenedicarboxamide; Imeron; Iomeron; Iomeron 350

15mg X

78649-41-9CAS:

Pentisomide α-[2-[Bis(1-methylethyl)amino]ethyl]-α-(2-methylpropyl)-2-pyridineacetamide;

2-[2-(Diisopropylamino)ethyl]-4-methyl]-2-(2-pyridyl) pentanamide; Propisomide; Penticainide; CM-7857; ME-3202;

15mg X

78833-03-1CAS:

Pidobenzone

5-oxo-L-Proline 4-Hydroxyphenyl Ester

15mg X

138506-45-3CAS:

Salcaprozate Sodium

8-[(2-Hydroxybenzoyl)amino]octanoic Acid Sodium Salt; 8-[(2- Hydroxybenzoyl)amino]octanoic Acid Monosodium Salt; E 414;

SNAC; Sodium 8-(Salicyloylamino)octanoate; Sodium 8-[(2- Hydroxybenzoyl)amino]caprylate; Sodium 8-[(2- Hydroxybenzoyl)amino]octanoate; Sodium N-[8-(2- Hydroxybenzoyl)amino]caprylate

15mg X

203787-91-1CAS:

9-(Benzylamino)-1,2,3,4-tetrahydroacridin-1-ol Maleate

1,2,3,4-Tetrahydro-9-[(phenylmethyl)amino]-1-acridinol (2Z) -2-Butenedioate; Suronacrine Hydrogen Maleate; Suronacrine Maleate;

15mg X

113108-86-4CAS:

Tiazofurin

2-β-D-Ribofuranosyl-4-thiazolecarboxamide; CI 909; NSC 286 -193; NSC 286193; Riboxamide; TCAR; Tiazofurine; 2-β-D- Ribofuranosylthiazole-4-carboxamide;

15mg X

60084-10-8CAS:

Cilofungin

1-[(4R,5R)-4,5-Dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-echinocandin B, 1H-Dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacycloheneicosine Cyclic Peptide derivative; Antibiotic LY 121019; L 646991;

(2α,3β,4β)-(4R,5R)-4,5-Dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-3-hydroxy-4-methyl-L-proline Cyclic (6→1)-peptide; LY 121019;

110mg X

79404-91-4CAS:

5α-Hydroxytriptolide

(3bR,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS) -3b,4,4a,6,6a,7a,7b,8b,9,10-Decahydro-3b,6-dihydroxy-8b-methyl-6a-(1-methylethyl)trisoxireno[4b,5:6,7:8a,9] phenanthro[1,2-c]furan-1(3H)-one; (-)-5α-Hydroxytryptolide;

(5R)-5-Hydroxytriptolide; LLDT 8; PG 701;

15mg X

583028-68-6CAS:

TS 011

N-[3-Chloro-4-(4-morpholinyl)phenyl]-N'-hydroxymethanimidamide

190mg X

339071-18-0CAS:

Galamustine Hydrochloride 1175mg X

Enpiroline αR)-rel-α-(2R)-2-Piperidinyl-2-(trifluoromethyl)-6-[4- (trifluoromethyl)phenyl]-4-pyridinemethanol; (R*,R*)-(±)-α-2- Piperidinyl-2-(trifluoromethyl)-6-[4-(trifluoromethyl)phenyl]-4-pyridinemethanol;

1275mg X

66364-73-6CAS:

Cefdaloxime

(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3- (methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid;

[6R-[6α,7β(Z)]]-7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3- (methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; (6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino] -3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid; RU 29246

1325mg X

80195-36-4CAS:

Cerlapirdine

N,N-Dimethyl-3-[[3-[(naphthalen-1-yl)sulfonyl]-1H-indazol-5-yl]oxy]propan-1-amine; SAM 531;

1560mg X

925448-93-7CAS:

Barucainide

4-[[1,3-Dihydro-6-methyl-4-(phenylmethyl)furo[3,4-c]pyridin -7-yl]oxy]-N-(1-methylethyl)-1-butanamine; Furo[3,4-c] pyridine 1-Butanamine derivative;

1125mg X

79784-22-8CAS:

Raluridine

2',3'-Dideoxy-3'-fluoro-5-chlorouridine; 5-Chloro-3'-fluoro -2',3'-dideoxyuridine; 935U83; BW 935U83; GW 274666X

1175mg X

119644-22-3CAS:

RTI-336

(1R,2S,3S,5S)-3-(4-Chlorophenyl)-8-methyl-2-[3-(4-methylphenyl)-5-isoxazolyl]-8-azabicyclo[3.2.1]octane Hydrochloride; [1R-(exo,exo)]-3-(4-Chlorophenyl)-8-methyl-2- [3-(4-methylphenyl)-5-isoxazolyl]-8-azabicyclo[3.2.1]octane Hydrochloride; RTI 336; RTI 4229-336;

1175mg X

204069-50-1CAS:

Repinotan Hydrochloride

BAY-x 3702; (R)-2-[4-[[(3,4-Dihydro-2H-1-benzopyran-2-yl) methyl]amino]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-Dioxide Monohydrochloride; (R)-2-(4-((Chroman-2-ylmethyl)amino) butyl)benzo[d]isothiazol-3(2H)-one 1,1-Dioxide Hydrochloride

1100mg X

144980-77-8CAS:

Pruvanserin Hydrochloride

1-[(3-Cyano-1H-indol-7-yl)carbonyl]-4-[2-(4-fluorophenyl) ethyl]piperazine Monohydrochloride; EMD 281014; LSN 2420586; LY 2422347 HCl; LY 2422347 Hydrochloride;

185mg X

443144-27-2CAS:

Zicronapine Fumarate

4-[(1R,3S)-6-Chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl]-1,2,2-trimethylpiperazine Fumarate; trans-(-)-4-(6-Chloro-2,3-dihydro-3-phenyl -1H-inden-1-yl)-1,2,2-trimethylpiperazine Fumarate; (-)-trans-4-[(1R,3S) -6-Chloro-3-phenylindan-1-yl]-1,2,2-trimethylpiperazine Hydrogen Fumarate; rel-(-)-4-[(1R,3S)-6-Chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl] -1,2,2-trimethylpiperazine (2E)-2-Butenedioate; trans-(-)-4-(6-chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl)-1,2,2-trimethylpiperazine (E)-2- Butenedioate

1150mg X

170381-17-6CAS:

Forasartan

5-[(3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol -5-yl)phenyl]pyridine; SC 52458

175mg X

145216-43-9CAS:

Pirquinozol

2-(Hydroxymethyl)pyrazolo[1,5-c]quinazolin-5(6H)-one; SQ 13847

160mg X

65950-99-4CAS:

Clazosentan

N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-2-pyridinesulfonamide; Ro 61-1790; VML 588;

1200mg X

180384-56-9CAS:

Tauromustine

2-[[[(2-Chloroethyl)nitrosoamino]carbonyl]amino]-N,N-dimethylethanesulfonamide; LS 2667; NSC 608678; TCNU;

150mg X

85977-49-7CAS:

Temocillin Disodium

(2S,5R,6S)-6-[(Carboxy-3-thienylacetyl)amino]-6-methoxy -3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Disodium Salt;‡[2S-(2α,5α,6α)]-6-[(Carboxy-3-thienylacetyl)amino]-6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Disodium Salt;

Antibiotic BRL 17421‡BRL 17421;

170mg X

61545-06-0CAS:

Anirolac

6-(4-Methoxybenzoyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic Acid; 2,3-Dihydro-5-(4-methoxybenzoyl)-1H-pyrrolizine-1-carboxylic Acid; RS 37326;

175mg X

66635-85-6CAS:

Esorubicin Hydrochloride

(8S,10S)-10-[[(2S,4R,6S)-4-Aminotetrahydro-6-methyl-2H-pyran-2-yl]oxy] -7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy -5,12-naphthacenedione Hydrochloride;

[2S-[2α(8R*,10R*),4β,6β]]-10-[(4-Aminotetrahydro-6-methyl-2H-pyran-2-yl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy -5,12-naphthacenedione Hydrochloride; (8S,10S)-10-[[(2S,4R,6S)-4- Aminotetrahydro-6-methyl-2H-pyran-2-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

130mg X

63950-06-1CAS:

Telapristone Acetate

CDB 4124; Proellex; Progenta; 17α-Acetoxy-11β-[4- (dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-dien -3,20-dione

130mg X

198414-31-2CAS:

Befloxatone

(5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone

170mg X

134564-82-2CAS:

Giripladib

4-[3-[5-Chloro-1-(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl) phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl] benzoic Acid; 4-(3-[5-Chloro-1-(diphenylmethyl)-2-[2-(((2- (trifluoromethyl)benzyl)sulfonyl)amino)ethyl]-1H-indole-3-yl] propyl)benzoic Acid; PLA 695

150mg X

865200-20-0CAS:

Trospectomycin Dihydrochloride

(2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-2-Butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-4H-pyrano[2,3-b][1,4] benzodioxin-4-one Dihydrochloride;

120mg X

85951-37-7CAS:

Eptaloprost

4-[(2E)-2-[(3aS,4S,5R,6aS)-Hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl]-2(1H)-pentalenylidene]ethoxy]butanoic Acid; [3aS- [2E,3aα,4α(3R*,4R*),5β,6aα]]-4-[2-[Hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]butanoic Acid;

4-[(2E)-2-[(3aS,4S,5R,6aS)-Hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiyn-1-yl]-2(1H)-pentalenylidene]ethoxy]butanoic Acid;

Eptaprost;

150mg X

90693-76-8CAS:

Enalkiren

N-(3-Amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N- [(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide; [1S-(1R*,2S*,3R*)]-N-(3-Amino -3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[1- (cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide;

150mg X

113082-98-7CAS:

Afacifenacin

(S)-(+)-3-[1-[3-(Trifluoromethoxy)benzyl]piperidin-4-yl]-4-phenyl-3,4-dihydro-1H-quinazolin-2-one

135mg X

877606-63-8CAS:

Plevitrexed

( S)- -[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl) methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole -5-butanoic Acid; BGC 9331; NSC 696259; ZD 9331; Vamidex;

145mg X

153537-73-6CAS:

Arzoxifene

2-(4-Methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-benzo[b]thiophene-6-ol; LY 353381

115mg X

182133-25-1CAS:

Enisoprost

(4Z, 11α, 13E) - (±) -11, 16- Dihydroxy- 16- methyl- 9- oxo- prosta- 4, 13- dien- 1- oic Acid Methyl Ester; SC 34301; (Z)-Methyl 7- ((1R,2R,3R)-3-Hydroxy-2-((E)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)hept-4-enoate;

125mg X

81026-63-3CAS:

Tanogitran Dihydrochloride 150mg X

253796-69-9CAS:

Savoxepin

3-(Cyclopentylmethyl)-2,3,4,5-tetrahydro-1H-dibenz[2,3:6,7] oxepino[4,5-d]azepine-7-carbonitrile; Cipazoxapine;

Savoxepine;

125mg X

79262-46-7CAS:

Bizelesin

N,N'-Bis[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol -5-yl]urea; (8S,8'S)-6,6'-[Carbonylbis(imino-1H-indole-5,2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methylbenzo[1,2-b:4,3-b']dipyrrol-4-ol; NSC 615291; U 77779;

1100mg X

129655-21-6CAS:

Vedroprevir

GS 9451; (1R,2R)-N-[[(1α,3β,5α)-bicyclo[3.1.0]hex-3-yloxy] carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-chloro-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-7-[2-(4-morpholinyl)ethoxy] -4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethyl-cyclopropanecarboxylic Acid

125mg X

1098189-15-1CAS:

Ataprost

[3aS-[2E,3aα,4α(1E,3R*),5β,6aα]]-5-[4-(3-Cyclopentyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene]pentanoic Acid; (5E)-5-[(3aS,4R,5R,6aS)-4- [(1E,3S)-3-Cyclopentyl-3-hydroxy-1-propenyl]hexahydro-5-hydroxy-2(1H)-pentalenylidene]pentanoic Acid; ONO 41483;

OP 41483;

155mg X

83997-19-7CAS:

4-Chloro Kynurenine α,2-Diamino-4-chloro-γ-oxobenzenebutanoic Acid; (+/-)-α,2- Diamino-4-chloro-γ-oxobenzenebutanoic Acid; 4-Cl-KYN; (+/-)-

AV-101;

15mg X

75802-84-5CAS:

Clentiazem

(+)-cis-2-(4-Methoxyphenyl)-3-acetoxy-5-[2-(N,N-dimethylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; (2S,3S)-3-(Acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; (2S-cis)-3-(Acetyloxy)-8-chloro-5-[2- (dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one;

15mg X

96125-53-0CAS:

52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment.

As prescribed in 4.2105(a), insert the following provision:

REPRESENTATION REGARDING CERTAIN TELECOMMUNICATIONS AND VIDEO SURVEILLANCE

SERVICES OR EQUIPMENT (OCT 2020)

The Offeror shall not complete the representation at paragraph (d)(1) of this provision if the Offeror has represented that it "does not provide covered telecommunications equipment or services as a part of its offered products or services to the Government in the performance of any contract, subcontract, or other contractual instrument" in paragraph (c)(1) in the provision at 52.204-26, Covered Telecommunications Equipment or Services—Representation, or in paragraph (v)(2)(i) of the provision at 52.212-3, Offeror Representations and Certifications-Commercial Items. The Offeror shall not complete the representation in paragraph (d)(2) of this provision if the Offeror has represented that it "does not use covered telecommunications equipment or services, or any equipment, system, or service that uses covered telecommunications equipment or services" in paragraph (c)(2) of the provision at 52.204-26, or in paragraph (v)(2)(ii) of the provision at 52.212-3.

(a) Definitions. As used in this provision—

Backhaul, covered telecommunications equipment or services, critical technology, interconnection arrangements, reasonable inquiry, roaming, and substantial or essential component have the meanings provided in the clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.

(b) Prohibition.

(1) Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. Nothing in the prohibition shall be construed to—

(i) Prohibit the head of an executive agency from procuring with an entity to provide a service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or https://www.acquisition.gov/far/part-4#FAR_4_2105 https://www.acquisition.gov/far/part-52#FAR_52_204_26 https://www.acquisition.gov/far/part-52#FAR_52_212_3 https://www.acquisition.gov/far/part-52#FAR_52_204_26 https://www.acquisition.gov/far/part-52#FAR_52_212_3 https://www.acquisition.gov/far/part-52#FAR_52_204_25

(ii) Cover telecommunications equipment that cannot route or redirect user data traffic or cannot permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(2) Section 889(a)(1)(B) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2020, from entering into a contract or extending or renewing a contract with an entity that uses any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. This prohibition applies to the use of covered telecommunications equipment or services, regardless of whether that use is in performance of work under a Federal contract. Nothing in the prohibition shall be construed to—

(i) Prohibit the head of an executive agency from procuring with an entity to provide a service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or

(ii) Cover telecommunications equipment that cannot route or redirect user data traffic or cannot permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(c) Procedures. The Offeror shall review the list of excluded parties in the System for Award Management (SAM) (https://www.sam.gov) for entities excluded from receiving federal awards for "covered telecommunications equipment or services".

(d) Representation. The Offeror represents that—

(1) It will, will not provide covered telecommunications equipment or services to the Government in the performance of any contract, subcontract or other contractual instrument resulting from this solicitation. The Offeror shall provide the additional disclosure information required at paragraph (e)(1) of this section if the Offeror responds "will" in paragraph (d)(1) of this section; and

(2) After conducting a reasonable inquiry, for purposes of this representation, the Offeror represents that—

It does, does not use covered telecommunications equipment or services, or use any equipment, system, or service that uses covered telecommunications equipment or services. The Offeror shall provide the additional disclosure information required at paragraph (e)(2) of this section if the Offeror responds "does" in paragraph (d)(2) of this section.

(e) Disclosures.

https://www.sam.gov/

(1) Disclosure for the representation in paragraph (d)(1) of this provision. If the Offeror has responded "will" in the representation in paragraph (d)(1) of this provision, the Offeror shall provide the following information as part of the offer:

(i) For covered equipment—

(A) The entity that produced the covered telecommunications equipment (include entity name, unique entity identifier, CAGE code, and whether the entity was the original equipment manufacturer (OEM) or a distributor, if known);

(B) A description of all covered telecommunications equipment offered (include brand; model number, such as OEM number, manufacturer part number, or wholesaler number; and item description, as applicable); and

(C) Explanation of the proposed use of covered telecommunications equipment and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b)(1) of this provision.

(ii) For covered services—

(A) If the service is related to item maintenance: A description of all covered telecommunications services offered (include on the item being maintained:

Brand; model number, such as OEM number, manufacturer part number, or wholesaler number; and item description, as applicable); or

(B) If not associated with maintenance, the Product Service Code (PSC) of the service being provided; and explanation of the proposed use of covered telecommunications services and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b)(1) of this provision.

(2) Disclosure for the representation in paragraph (d)(2) of this provision. If the Offeror has responded "does" in the representation in paragraph (d)(2) of this provision, the Offeror shall provide the following information as part of the offer:

(i) For covered equipment—

(A) The entity that produced the covered telecommunications equipment (include entity name, unique entity identifier, CAGE code, and whether the entity was the OEM or a distributor, if known);

(B) A description of all covered telecommunications equipment offered (include brand; model number, such as OEM number, manufacturer part number, or wholesaler number; and item description, as applicable); and

(C) Explanation of the proposed use of covered telecommunications equipment and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b)(2) of this provision.

(ii) For covered services—

(A) If the service is related to item maintenance: A description of all covered telecommunications services offered (include on the item being maintained:

Brand; model number, such as OEM number, manufacturer part number, or wholesaler number; and item description, as applicable); or

(B) If not associated with maintenance, the PSC of the service being provided; and explanation of the proposed use of covered telecommunications services and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b)(2) of this provision.

(End of provision)

CERTIFICATION:

Name of Authorized Individual Signature of Authorized Individual Date

Title Name of Organization